Products & Services · Total revenues
AMVUTTRA — Total revenues
Alnylam Pharmaceuticals AMVUTTRA — Total revenues increased by 7.7% to $889.93M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 187.1%, from $309.99M to $889.93M. Over 3 years (FY 2022 to FY 2025), AMVUTTRA — Total revenues shows an upward trend with a 191.1% CAGR.
Analysis
Metric ID:
alny_segment_amvuttra_total_revenuesHistorical Data
19 periods
| Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0 | $0 | $0 | $0 | $25.23M | $68.57M | $101.77M | $132.14M | $148.68M | $175.25M | $195.24M | $230.11M | $258.59M | $286.51M | $309.99M | $491.95M | $685.3M | $826.59M | $889.93M |
| QoQ Change | — | — | — | — | — | +171.8% | +48.4% | +29.8% | +12.5% | +17.9% | +11.4% | +17.9% | +12.4% | +10.8% | +8.2% | +58.7% | +39.3% | +20.6% | +7.7% |
| YoY Change | — | — | — | — | — | — | — | — | +489.3% | +155.6% | +91.8% | +74.1% | +73.9% | +63.5% | +58.8% | +113.8% | +165.0% | +188.5% | +187.1% |
Range$0 – $889.93M
Avg YoY Growth+151.0%
Median YoY Growth+113.8%
Current Streak14+ quarters growth
Frequently Asked Questions
- What is Alnylam Pharmaceuticals's amvuttra — total revenues?
- Alnylam Pharmaceuticals (ALNY) reported amvuttra — total revenues of $889.93M in Q1 2026.
- How has Alnylam Pharmaceuticals's amvuttra — total revenues changed year-over-year?
- Alnylam Pharmaceuticals's amvuttra — total revenues increased by 187.1% year-over-year, from $309.99M to $889.93M.
- What is the long-term trend for Alnylam Pharmaceuticals's amvuttra — total revenues?
- Over 3 years (2022 to 2025), Alnylam Pharmaceuticals's amvuttra — total revenues has grown at a 191.1% compound annual growth rate (CAGR), from $93.8M to $2.31B.